Bioassay Genetic Engineering Genetics Research 
Drug Discovery World
NOVEMBER 9, 2023
Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.
Drug Discovery World
MAY 10, 2023
While the discovery phase – which includes target discovery, target validation, lead compound identification, and lead compound optimisation – averages several years and $200 million, the majority of the research, time, and financial spend takes place downstream in drug development. In practice, this was typically conducted in rats and mice.
Expert insights. Personalized for you.
52 
Let's personalize your content